Ipsen S.A.
OTC: IPSEF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- David G. Loew
- Employees
- 5,535
- Headquarters
- Paris, France
- IPO year
- 2009
- Market cap
- $9.4B
- Website
- http://www.ipsen.com
Loading IPSEF…
Loading profile data…Frequently asked questions about IPSEF
What does Ipsen S.A. (IPSEF) do?
Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Its oncology products include Somatuline for the treatment of neuroendocrine tumors and acromegaly; Cabometyx, a tyrosine kinase inhibitor to treat second line pancreatic and extra-pancreatic neuroend...
Where does IPSEF trade?
Ipsen S.A. (IPSEF) trades on the Other OTC.
What sector is IPSEF in?
Ipsen S.A. (IPSEF) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Ipsen S.A.?
David G. Loew is the chief executive officer of Ipsen S.A. (IPSEF).
Where is Ipsen S.A. headquartered?
Ipsen S.A. is headquartered in France.
Does IPSEF pay a dividend?
Yes — Ipsen S.A. (IPSEF) paid a trailing twelve-month dividend of USD 1.86 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did IPSEF go public?
Ipsen S.A. (IPSEF) completed its initial public offering in 2009.